… Pirfenidone is 1 of 2 approved IPF treatments. … and pirfenidone may address unmet needs
in patients with IPF and PH. MA29957 (NCT02951429) is an ongoing study assessing the …

… We found that after controlling ICIP, some patients continued to receive pirfenidone
maintenance therapy (300 mg 3 times a day), which showed some advantages in controlling the …

… Oral pirfenidone was generally associated with beneficial … in patients receiving the approved
target dosage of pirfenidone (ie … Patients received pirfenidone 2403 mg/day or placebo in …

… of pirfenidone in IPF patients. In both Japanese trials and CAPACITY trials, the efficacies …
pirfenidone have been shown in partial populations of patients with IPF, not in all IPF patients…

… Two of these novel agents, Pirfenidone, an orally bioavailable … safety of pirfenidone and
nintedanib to treat patients with IPF … doses of pirfenidone and nintedanib (pirfenidone 1,800 or …

… comprehensive panel of markers of OS and inflammation in IPF patients before and after
24-week treatment with pirfenidone … In particular we assessed the plasma concentrations of: (i) …

… pirfenidone might be a promising drug for RILI prevention. This study aims to evaluate the
efficacy and safety of pirfenidone in preventing RILI in patients … addition of pirfenidone during …

Background Pirfenidone (PFD) is widely used in patients with idiopathic pulmonary fibrosis (IPF)
and its adverse effects, such as nausea and photosensitivity, are well known. Many …

… growth factor beta inhibition via Pirfenidone by using flow cytometry, In-Cell … comprehensive
analyses of the transcriptome with subsequent bioinformatics analysis. Overall, Pirfenidone …

… -controlled trial that assessed the efficacy and safety of sildenafil plus pirfenidone over 52
weeks in patients with advanced IPF at risk of PH. METHODS: Patients had advanced IPF (…